MB-001
Sponsors
Mage Biologics Inc., Mage Biologics
Conditions
Ulcerative ColitisUlcerative Colitis (UC)
Phase 1
A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants
CompletedNCT06363383
Start: 2024-05-09End: 2025-07-04Updated: 2025-09-30
A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis
RecruitingNCT07374471
Start: 2026-04-01End: 2028-08-01Target: 100Updated: 2026-04-14
A Phase 1b/2a, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MB-001 in Participants With Moderately to Severely Active Ulcerative Colitis
Not yet recruitingCTIS2025-524719-35-00
Target: 30Updated: 2026-04-29